» Articles » PMID: 27068720

2015 David Y. Graham Lecture: The First Two Decades Of Eosinophilic Esophagitis-From Acid Reflux To Food Allergy

Overview
Specialty Gastroenterology
Date 2016 Apr 13
PMID 27068720
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Collaborative efforts by pediatric and adult gastroenterologists, allergists, dieticians, and pathologists have brought about marked progress in the recognition, understanding, and management of eosinophilic esophagitis (EoE) over the past two decades. Once an esoteric diagnosis, EoE is now increasingly identified as a major cause of morbidity, afflicting both children and adults. The detection of mucosal eosinophils has evolved from a diagnostic feature of acid reflux to a biomarker of food sensitization of the esophagus. Translational studies and murine models have elucidated Th-2 immune pathways in EoE, inspiring the development of targeted biologic therapeutics. At the same time, validation of patient-reported outcomes and endoscopic end points has facilitated the implementation of clinical trials of novel therapeutics. Ongoing investigations have elucidated the importance of "looking beneath the surface" of the epithelium, focusing greater attention on the impact of esophageal remodeling in the clinical consequences of EoE. Elimination diets continue to gain popularity as an intriguing, highly effective, and non-pharmacologic therapy that lends credence to the concept that EoE is a food-driven, immunologic disorder.

Citing Articles

Clinicopathological Differences between Eosinophilic Esophagitis and Asymptomatic Esophageal Eosinophilia.

Suzuki Y, Iizuka T, Hosoi A, Kikuchi D, Okamura T, Ochiai Y Intern Med. 2021; 61(9):1319-1327.

PMID: 34670895 PMC: 9152855. DOI: 10.2169/internalmedicine.8241-21.


.

Raithel M, Bischoff S Allergo J. 2020; 29(8):40-44.

PMID: 33343098 PMC: 7735185. DOI: 10.1007/s15007-020-2647-6.


Challenges and updates in the management of eosinophilic esophagitis.

Velikova T Prz Gastroenterol. 2020; 15(1):27-33.

PMID: 32215124 PMC: 7089863. DOI: 10.5114/pg.2019.84476.


Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension.

Hudgens S, Evans C, Phillips E, Hill M J Patient Rep Outcomes. 2018; 1(1):3.

PMID: 29757322 PMC: 5934937. DOI: 10.1186/s41687-017-0006-5.


Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Cheng K, Gupta S, Kantor S, Kuhl J, Aceves S, Bonis P Transl Sci Rare Dis. 2018; 2(3-4):141-155.

PMID: 29333363 PMC: 5757645. DOI: 10.3233/TRD-170016.


References
1.
Morrow J, Vargo J, Goldblum J, Richter J . The ringed esophagus: histological features of GERD. Am J Gastroenterol. 2001; 96(4):984-9. DOI: 10.1111/j.1572-0241.2001.03682.x. View

2.
Aceves S, Ackerman S . Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am. 2009; 29(1):197-211, xiii-xiv. PMC: 2665721. DOI: 10.1016/j.iac.2008.10.003. View

3.
Furuta G, Liacouras C, Collins M, Gupta S, Justinich C, Putnam P . Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007; 133(4):1342-63. DOI: 10.1053/j.gastro.2007.08.017. View

4.
Kia L, Hirano I . Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. Nat Rev Gastroenterol Hepatol. 2015; 12(7):379-386. PMC: 4948861. DOI: 10.1038/nrgastro.2015.75. View

5.
Lexmond W, Pardo M, Rooney K, Goettel J, Snapper S, Yen E . Elevated levels of leukotriene C4 synthase mRNA distinguish a subpopulation of eosinophilic oesophagitis patients. Clin Exp Allergy. 2013; 43(8):902-13. PMC: 3728707. DOI: 10.1111/cea.12146. View